Network Pharmacology and Molecular Docking Study on the Potential Mechanism of Yi-Qi-Huo-Xue-Tong-Luo Formula in Treating Diabetic Peripheral Neuropathy

Abstract

Objective. To investigate the potential mechanism of action of Yi-Qi-Huo-Xue-Tong-Luo formula (YQHXTLF) in the treatment of diabetic peripheral neuropathy (DPN). Methods. Network pharmacology and molecular docking techniques were used in this study. Firstly, the active ingredients and the corresponding targets of YQHXTLF were retrieved using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) platform; subsequently, the targets related to DPN were retrieved using GeneCards, Online Mendelian Inheritance in Man (OMIM), Pharmgkb, Therapeutic Target Database (TTD) and Drugbank databases; the common targets of YQHXTLF and DPN were obtained by Venn diagram; afterwards, the “YQHXTLF Pharmacodynamic Component-DPN Target” regulatory network was visualized using Cytoscape 3.6.1 software, and Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed on the potential targets using R 3.6.3 software. Finally, molecular docking of the main chemical components in the PPI network with the core targets was verified by Autodock Vina software. Results. A total of 86 active ingredients and 229 targets in YQHXTLF were screened, and 81 active ingredients and 110 targets were identified to be closely related to diabetic peripheral neuropathy disease. PPI network mapping identified TP53, MAPK1, JUN, and STAT3 as possible core targets. KEGG pathway analysis showed that these targets are mostly involved in AGE-RAGE signaling pathway in diabetic complications, TNF signaling pathway, and MAPK signaling pathway. The molecular docking results showed that the main chemical components of YQHXTLF have a stable binding activity to the core pivotal targets. Conclusion. YQHXTLF may act on TP53, MAPK1, JUN, and STAT3 to regulate inflammatory response, apoptosis, or proliferation as a molecular mechanism for the treatment of diabetic peripheral neuropathy, reflecting its multitarget and multipathway action, and providing new ideas to further uncover its pharmacological basis and mechanism of action.

Network Pharmacology and Molecular Docking Analysis on Pharmacological Mechanisms of Astragalus membranaceus in the Treatment of Gastric Ulcer

“…According to the principle of molecular docking, the smaller the binding energy, the more stable the docking module. The minimum binding energy <−5.0 kcal/mol indicates that a good binding affinity is between receptor and ligand, and the minimum binding energy <−7.0 kcal/mol represents that the binding affinity was extremely strong [ 33 , 34 ]. Finally, the docking results with binding energy <−7.0 kcal/mol were visualized by utilizing PyMOL v2.1.0.…”

Antioxidant Effects and Potential Molecular Mechanism of Action of Limonium aureum Extract Based on Systematic Network Pharmacology

“…The keyword “antioxidant” was used to search disease-related genes on GeneCards database ( 40 ) (available online: https://www.genecards.org/ , last updated in October 2021) ( 41 ), and the antioxidant-related genes were collected with the setting of relevance score of ≥30. The bioactive ingredients targets of L. aureum were mapped to the target genes related to antioxidant to obtain the common target genes through the online tool “jvenn” (available online: http://jvenn.toulouse.inra.fr/app/example.html ).…”

Exploring the Molecular Mechanism of Tong Xie Yao Fang in Treating Ulcerative Colitis Using Network Pharmacology and Molecular Docking

“…Evidence-Based Complementary and Alternative Medicine Evidence-Based Complementary and Alternative Medicine Docking modules are considered more stable when their binding energy is smaller [28]. In terms of minimum binding energy, a value lower than −5.0 kcal/mol indicates a good affinity between receptor and ligand, and a value lower than −7.0 kcal/mol indicates a very strong affinity between receptor and ligand [29,30]. To better evaluate the docking result, we also downloaded mesalazine-D3 (CID: 71750020) from PubChem database as ligand to perform molecular docking.…”